Shrinkage of Prostate and Improved Quality of Life: Management of BPH Patients with Croton membranaceus Ethanolic Root Extract

الملخص EN

Benign prostatic hyperplasia (BPH) is an enlargement of the prostate.

The study aimed at validating the use of freeze-dried Croton membranaceus ethanolic root extract for BPH management.

Thirty-three patients were observed before and after 3-month administration of 20 mg t.i.d orally.

The International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIEF) questionnaires were used.

Total/free PSA (tPSA, fPSA), renal, liver function, lipid tests, and ultrasonographic imaging were performed.

Thirty (30) patients (66 ± 11 years) completed the study.

IPSS results showed 37% had severe, 40% moderate, and 23% mild symptoms before; 57% and 43% had moderate and mild symptoms, respectively, after treatment.

IIED of patients’ results showed 30% with severe, 40% moderate, 24% mild-moderate, 3% mild, and 3% no erectile dysfunction before treatment and 20% severe, 43% moderate, and 37% mild-moderate dysfunction, after treatment.

Quality of life (QoL) improved ( P = 0.001 ) .

Significant but non-pathological increases in total and indirect bilirubin as well as apolipoprotein A occurred.

Mean tPSA reduced from 27.9 ± 19.0 to 16.2 ± 11.8 ng/mL ( P = 0.002 ) ; fPSA from 6.1 ± 4.8 to 3.9 ± 2.9 ng/mL ( P = 0.045 ) ; and prostate volume from 101.8 ± 41.3 to 54.5 ± 24.8 cm3 ( P = 0.023 ) .

C.

membranaceus shrinks the prostate and improves QoL.